Landos Biopharma, Inc. (LABP) — Financial statements
Income statement, balance sheet, and cash flow for Landos Biopharma, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00↓100.0% | 18 | 0.00 | 0.00 | |
| Cost of Revenue | 0.00↓100.0% | 0.58↑194.4% | 0.20↑43.1% | 0.14↑33.0% | 0.10 | |
| Gross Profit | 0.00↑100.0% | -0.58↓103.2% | 18↑13095.6% | -0.14↓33.0% | -0.10 | |
| Operating Expenses | ||||||
| R&D Expenses | 12↓53.3% | 26↓38.2% | 42↑64.0% | 25↑114.5% | 12 | |
| General & Administrative Expenses | 11↓27.9% | 15↓2.4% | 15↑185.7% | 5↑261.2% | 1 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 11↓27.9% | 15↓2.4% | 15↑185.7% | 5↑261.2% | 1 | |
| Other Expenses | 0.00↓100.0% | 1↑226.1% | 0.39 | 0.00 | 0.00 | |
| Operating Expenses | 23↓44.0% | 41↓28.6% | 57↑85.2% | 31↑130.8% | 13 | |
| Total Costs & Expenses | 23↓44.0% | 41↓28.6% | 57↑85.2% | 31↑130.8% | 13 | |
| Operating Results | ||||||
| Operating Income | -23↑44.0% | -41↓4.5% | -39↓26.5% | -31↓130.8% | -13 | |
| Depreciation & Amortization | 0.04↓92.4% | 0.58↑194.4% | 0.20↓66.9% | 0.59↑125.1% | 0.26 | |
| EBITDA | -23↑42.2% | -39↓1.7% | -39↓28.4% | -30↓130.9% | -13 | |
| EBIT | -23↑43.0% | -40↓2.7% | -39↓26.5% | -31↓133.0% | -13 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.00 | 0.00↓100.0% | 0.41↓9.5% | 0.46↑249.7% | -0.30 | |
| Interest Income | 0.00 | 0.00↓100.0% | 0.41↓9.5% | 0.46 | 0.00 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00↓100.0% | 0.30 | |
| Non-Operating Income | 0.00↑100.0% | -0.71 | 0.00 | 0.00↑100.0% | -0.13 | |
| Other Income / Expenses | 0.79↓38.4% | 1↑226.1% | 0.39↓25.9% | 0.53↑400.6% | -0.18 | |
| Income Before Tax | -22↑44.2% | -39↓2.2% | -38↓27.5% | -30↓123.8% | -13 | |
| Income Tax Expense | 0.00↑100.0% | -1↓555.6% | -0.20 | 0.00↓100.0% | 0.46 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -22↑42.3% | -38↑0.6% | -38↓26.8% | -30↓116.4% | -14 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -22↑42.3% | -38↑0.6% | -38↓26.8% | -30↓116.4% | -14 | |
| Bottom-Line Net Income | -22↑42.3% | -38↑0.6% | -38↓26.8% | -30↓116.4% | -14 | |
| EPS (Basic) | -3.50↑62.9% | -9.44↑0.6% | -9.50↓26.5% | -7.51↓116.4% | -3.47 | |
| EPS (Diluted) | -3.50↑62.9% | -9.44↑0.6% | -9.50↓26.5% | -7.51↓116.4% | -3.47 | |
| Weighted Average Shares | 6↑55.9% | 4↑0.0% | 4↑0.3% | 4↑0.0% | 4 | |
| Weighted Average Diluted Shares | 6↑55.9% | 4↑0.0% | 4↑0.3% | 4↑0.0% | 4 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.